Form 4 Medtronic plc For: Aug 15 Filed by: Corona Gary Louis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
August 21, 2024 6:52 AM EDTGoldman Sachs analyst David Roman reiterated a Sell rating and $82.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "Following 1QFY25, we revise our model for (1) recent business performance; (2) updated market outlooks and competitive positioning; and (3) P&L assumptions. For FY25, we land just below EBIT margin targets, driven by sustained... More
Medtronic, Inc. (MDT) PT Raised to $94 at Oppenheimer
August 21, 2024 6:48 AM EDTOppenheimer analyst Steven Lichtman raised the price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $92.00) while maintaining a Perform rating.
The analyst comments "Medtronic raised FY25 guidance low-end on organic sales (4.5-5% vs. 4-5% prior) and EPS (up slightly to $5.42-5.50 vs. $5.405.50). F1Q... More
Medtronic, Inc. (MDT) PT Raised to $106 at Wells Fargo
August 21, 2024 5:19 AM EDTWells Fargo analyst Larry Biegelsen raised the price target on Medtronic, Inc. (NYSE: MDT) to $106.00 (from $105.00) while maintaining a Overweight rating.
The analyst comments "Strong FQ1 rev beat on CVG, Neuroscience, and Diabetes strength. MDT reported FQ1 2025 rev of $8.0B (+5.3% organic) exceeded... More
Wolfe Research Reiterates Underperform Rating on Medtronic, Inc. (MDT)
August 21, 2024 5:13 AM EDTWolfe Research analyst Mike Polark reiterated an Underperform rating and $82.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "We rate MDT shares Underperform. We have an $82 target price which simplistically represents a 15x multiple on our FY2025 adjusted EPS forecast. On FY2025 EPS, our 15 P/E input represents a ~25% discount to current CY25 S&P 500 multiple of ~20x. This discount to the S&P sits in bottom quartile of the last decade. A discount is warranted, in our view, on track record and short-run expectations. Back 12 years, MDT EPS has... More
Deutsche Bank Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 21, 2024 5:10 AM EDTDeutsche Bank analyst Pito Chickering reiterated a Hold rating and $85.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "MDT outperformed the broader market by 100 bps post this mornings print, with shareholders frustrated that MDT didnt outperform more post the beat-and-raise. MDT now... More
